Factor V Leiden and Prothrombin G20210A Mutations and the Risk of Atherothrombotic Events in Systemic Lupus Erythematosus

Abstract

Because genetic predisposition to atherothrombosis in systemic lupus erythematosus (SLE) remains to be determined, the most common genetic prothrombotic factors, prothrombin G20210A and factor V Leiden mutations, were studied. Seventy-four SLE patients with vascular ischemia (SLE cases) were studied and stratified into myocardial infarction and/or cerebrovascular accident subgroup (MI/CVA), and coronary heart disease subgroup without overt arterial thrombotic events (CHD). Seventy-one SLE patients without atherothrombosis were investigated as SLE controls. Factor V Leiden was detected in six cases (five in MI/CVA, one in CHD group) and three controls (OR 2.00, 95%CI 0.48-8.32). Two cases (both CHD patients) had prothrombin G20210A mutation vs. three controls (OR 0.63, 95%CI 0.1-3.88). Anticardiolipin antibodies (aCL) were increased in cases vs. controls (39/74 vs. 27/71); however, this was not statistically significant (OR 1.82, 95%CI 0.94-3.52). Neither univariate nor multivariate analysis indicated that investigated mutations are risk factors for atherothrombosis in SLE cases, MI/CVA, or CHD subgroups. Overall, disease activity was the strongest risk factor for atherothrombosis (p=0.0014) in SLE cases. Combination of disease activity+gender was the best predictor of atherothrombotic process (p=0.00045) in this cohort. In MI/CVA subgroup, disease activity was the only predictor (p=0.0058). In CHD patients, the best predictive value was conferred by combination of hypertension+gender+disease activity (p=0.00077). No other investigated risk factor (including aCL) conferred an increased risk individually or potentiated the other risk factors. The results deny the role of investigated mutations in atherothrombosis in SLE, but they underscore the importance of disease activity (i.e., ongoing inflammation) in pathogenesis of atherosclerosis and arterial thrombosis.

Keywords

Factor V Leiden Prothrombin G20210A Atherosclerosis Arterial thrombosis SLE

References

Petri M. Cardiovascular morbidity in the Hopkins Lupus Cohort. In: Shoenfeld Y , Harats D , Wick G (eds). Atherosclerosis and Autoimmunity. New York: Elsevier Science; 2001, pp 249-254.

Manzi S , Meilahn EN , Rairie JE , et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study. Am J Epidemiol 1997;145:408.

Esdaile JM , Abrahamowicz M , Grodzicky T , et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331.

Futrell N , Millikan C. Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke 1989;20:583.

Nencini P , Pracucci G , Lamassa M , Amaducci L , Inzitari D. Immunological factors predict a poor long term outcome in young stroke patients. Lupus 1994;3:314.

Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000;9:170.

Manzi S.

Systemic lupus erythematosus: A model for atherogenesis?

Rheumatology (Oxford) 2000;39:353.

Salmon JE , Roman MJ . Accelerated atherosclerosis in systemic lupus erythematosus: Implications for patient management. Curr Opin Rheumatol 2001;13:341.

Lockshin MD , Salmon JE , Roman MJ . Atherosclerosis and lupus: A work in progress. Arthritis Rheum 2001;44:2215.

10.

Svenungsson E , Jensen-Urstad K , Heimburger M , et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104:1887.

11.

Lau EC . Genetics of arterial thrombosis: Contribution to Atherosclerosis. In: Shoenfeld Y , Harats D , Wick G (eds). Atherosclerosis and Autoimmunity. New York: Elsevier Science; 2001, pp 341-358.

12.

Simmonds RE , Hermida J , Rezende SM , Lane DA . Haemostatic genetic risk factors in arterial thrombosis. Thromb Haemost 2001;86:374.

13.

Boekholdt SM , Bijsterveld NR , Moons AH , Levi M , Buller HR , Peters RJ . Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: A systematic review. Circulation 2001;104:3063.

14.

Rosendaal FR , Siscovick DS , Schwartz SM , et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817.

15.

De Stefano V , Chiusolo P , Paciaroni K , et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998;91:3562.

16.

Burzotta F , Paciaroni K , De Stefano V , et al. Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. Eur Heart J 2002;23:26.

17.

Doggen CJ , Cats VM , Bertina RM , Rosendaal FR . Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998;97:1037.

18.

Tan EM , Cohen AS , Fries JF , et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271.

19.

Bombardier C , Gladman DD , Urowitz MB , Caron D , Chang CH . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630.

20.

Poort SR , Rosendaal FR , Reitsma PH , Bertina RM . A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698.

21.

Ridker PM , Hennekens CH , Lindpaintner K , Stampfer MJ , Eisenberg PR , Miletich JP . Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912.

22.

Chopra N , Koren S , Greer WL , et al. Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies. J Rheumatol 2002;29:1683.

23.

Topaloglu R , Akierli C , Bakkaloglu A , et al. Survey of factor V Leiden and prothrombin gene mutations in systemic lupus erythematosus. Clin Rheumatol 2001;20:259.

24.

Gordon PA , George J , Khamashta MA , Harats D , Hughes G , Shoenfeld Y. Atherosclerosis and autoimmunity. Lupus 2001;10:249.

25.

Miller LW . Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002;2:807.

26.

Pullmann R Jr , Škereňová M , Lukáč J , et al. Letter to editor: No role of factor V Leiden and prothrombin G20210 mutations in pathogenesis and arterial thrombosis in systemic lupus erythematosus. Clin Exp Rheumatol, in press.

27.

Pablos JL , Caliz RA , Carreira PE , et al. Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. J Rheumatol 1999;26:588.

28.

Bertolaccini ML , Atsumi T , Hunt BJ , Amengual O , Khamashta MA , Hughes GR . Prothrombin mutation is not associated with thrombosis in patients with antiphospholipid syndrome. Thromb Haemost 1998;80:202.